

CURIS INC  
Form 8-K  
September 01, 2011

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): August 29, 2011**

**Curis, Inc.**

**(Exact Name of Registrant as Specified in Charter)**

**Delaware**  
**(State or Other Jurisdiction**  
  
**of Incorporation)**

**000- 30347**  
**(Commission**  
  
**File Number)**

**04-3505116**  
**(IRS Employer**  
  
**Identification No.)**

Edgar Filing: CURIS INC - Form 8-K

**4 Maguire Road, Lexington, MA**  
(Address of Principal Executive Offices)

**Registrant's telephone number, including area code: (617) 503-6500**

**02421**  
(Zip Code)

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On August 29, 2011, Mitchell Keegan, Ph.D., the Vice President of Drug Development of Curis, Inc. (the Company ) provided notice of his intention to resign from the Company, effective on or about October 15, 2011.

Kenneth J. Pienta, M.D., the Chairman of the Company's Clinical and Scientific Advisory Board, will continue to provide advisory services to the Company in the area of drug development both during and after Dr. Keegan's transition.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 1, 2011

By: /s/ Michael P. Gray

Michael P. Gray

Chief Operating Officer and Chief Financial Officer